SINTAX: The Small Intestine is a Big Deal
Our SINTAX platform has the potential to transform the global treatment of all stages of inflammatory disease. We’re working to harness the connection between the small intestine and the rest of the body to develop orally-delivered medicines that act in the small intestine to exert wide-ranging therapeutic effects.
Messages passing from the small intestine to the rest of the body govern inflammation, as well as many other physiological functions. Cells in the small intestine play a central role in governing the:
- Immune system
- Metabolic system
- Neurological system
The unique profile of SINTAX-based medicines could allow us to provide a new class of effective, safe and well-tolerated, oral and convenient, and affordable to millions of people across all stages of disease.
Discover how we’re responding to the worldwide inflammation crisis
The Mechanism of Action
Our orally-delivered, gut-restricted commensal microbial medicines can resolve inflammation in peripheral tissues like the skin without ever leaving the intestine or altering the microbiome. Depending on the bacterial strain, each microbe can initiate and amplify immune signaling cascades by reprogramming cells of the small intestine which then go on to modulate effector cells in the lymph nodes to reset the immune system to homeostasis.
Watch our MOA video
Our Product Candidates
Our product candidates have the potential to target diseases ranging from inflammatory conditions such as psoriasis, atopic dermatitis, asthma, food allergies, arthritis, inflammatory bowel disease, and neuroinflammatory diseases.
In preclinical and clinical studies, we have observed that our product candidates are well tolerated with no overall difference reported from placebo. Data show that SINTAX-based candidates have meaningful clinical effects.
Next-Generation Product Candidates
In order to capture the full potential of SINTAX medicines across different biologies and diseases, we are also advancing microbial extracellular vesicles (EVs) as our next generation of product candidates. Currently in preclinical development, Evelo has seen positive effects of pharmaceutical preparations of bacterial EVs from single strains, delivered orally.
Our IP estate provides several layers of protection for our therapies. We have multiple issued patents and many pending patent applications covering our product candidates and platform technology. Our current patent estate is expected, based on the particular patent or application, to provide patent protection that will expire between the late 2020s and early 2040s.
We Want to Hear From You
Let’s start the conversation. For inquiries or requests for more information, reach out.